[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Mikaelsdottir et al., 2021 - Google Patents

A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven‐day storage

Mikaelsdottir et al., 2021

Document ID
6866662468836128131
Author
Mikaelsdottir M
Vidarsson B
Runarsson G
Bjarnadottir U
Onundarson P
Sigurjonsson O
Halldorsdottir A
Publication year
Publication venue
Transfusion

External Links

Snippet

Background Therapeutic phlebotomy is the standard treatment of hereditary hemochromatosis (HH), the most common genetic disease in people of Northern European descent. Red cell concentrates from HH donors have been reported safe for transfusion, but …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood

Similar Documents

Publication Publication Date Title
Johnson et al. In vitro comparison of cryopreserved and liquid platelets: potential clinical implications
García-Roa et al. Red blood cell storage time and transfusion: current practice, concerns and future perspectives
Johnson et al. The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine‐expressing platelets and platelet microparticles
Hess Measures of stored red blood cell quality
Albanyan et al. Markers of platelet activation and apoptosis during storage of apheresis‐and buffy coat–derived platelet concentrates for 7 days
Raval et al. The use of the mechanical fragility test in evaluating sublethal RBC injury during storage
Hess Conventional blood banking and blood component storage regulation: opportunities for improvement
Mykhailova et al. Donor‐dependent aging of young and old red blood cell subpopulations: Metabolic and functional heterogeneity
Sparrow et al. In vitro measures of membrane changes reveal differences between red blood cells stored in saline‐adenine‐glucose‐mannitol and AS‐1 additive solutions: a paired study
Johnson et al. Evaluation of the quality of blood components prepared using the Reveos automated blood processing system
Lelkens et al. Prolonged post‐thaw shelf life of red cells frozen without prefreeze removal of excess glycerol
Johnson et al. Refrigeration of apheresis platelets in platelet additive solution (PAS‐E) supports in vitro platelet quality to maximize the shelf‐life
Sheffield et al. Changes in coagulation factor activity and content of di (2‐ethylhexyl) phthalate in frozen plasma units during refrigerated storage for up to five days after thawing
Black et al. Analysis of platelet‐derived extracellular vesicles in plateletpheresis concentrates: a multicenter study
Vetlesen et al. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system
Getz et al. Sodium citrate contributes to the platelet storage lesion
Sandgren et al. Storage of platelet concentrates from pooled buffy coats made of fresh and overnight‐stored whole blood processed on the novel Atreus 2C+ system: in vitro study
Singh et al. Platelet storage lesion in interim platelet unit concentrates: A comparison with buffy-coat and apheresis concentrates
Bashir et al. Lipaemic plasma induces haemolysis in resuspended red cell concentrate
Wagner et al. Impact of constant storage temperatures and multiple warming cycles on the quality of stored red blood cells
Tiwari-Heckler et al. Extracellular mitochondria drive CD8 T cell dysfunction in trauma by upregulating CD39
Mikaelsdottir et al. A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven‐day storage
Stefani et al. Effects of leukoreduction on storage lesions in whole blood and blood components of dogs
Johnson et al. The role of sodium citrate during extended cold storage of platelets in platelet additive solutions
Vucic et al. Evaluation of platelet activation in leukocyte-depleted platelet concentrates during storage